410 related articles for article (PubMed ID: 32671454)
41. Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation.
Menke JR; Vasmatzis G; Murphy S; Yang L; Menke DM; Tun HW; King RL; Smoley SA; Ketterling RP; Sukov WR
Hum Pathol; 2017 Jun; 64():207-212. PubMed ID: 28132860
[TBL] [Abstract][Full Text] [Related]
42. A second case of secondary acute myeloblastic leukemia associated with the MLL-KIAA0284 fusion gene.
De Braekeleer E; Ianotto JC; Douet-Guilbert N; Meyer C; Morel F; Le Bris MJ; Marschalek R; Berthou C; Férec C; De Braekeleer M
Blood Cells Mol Dis; 2009; 42(3):292-3. PubMed ID: 19254855
[No Abstract] [Full Text] [Related]
43. Molecular pathogenesis of mantle cell lymphoma.
Jares P; Colomer D; Campo E
J Clin Invest; 2012 Oct; 122(10):3416-23. PubMed ID: 23023712
[TBL] [Abstract][Full Text] [Related]
44. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
Visco C; Di Rocco A; Evangelista A; Quaglia FM; Tisi MC; Morello L; Zilioli VR; Rusconi C; Hohaus S; Sciarra R; Re A; Tecchio C; Chiappella A; Marin-Niebla A; McCulloch R; Gini G; Perrone T; Nassi L; Pennese E; Stefani PM; Cox MC; Bozzoli V; Fabbri A; Polli V; Ferrero S; Celis MIA; Sica A; Petrucci L; Arcaini L; Rule S; Krampera M; Vitolo U; Balzarotti M
Leukemia; 2021 Mar; 35(3):787-795. PubMed ID: 32782382
[TBL] [Abstract][Full Text] [Related]
45. Advances in the assessment of minimal residual disease in mantle cell lymphoma.
Jung D; Jain P; Yao Y; Wang M
J Hematol Oncol; 2020 Sep; 13(1):127. PubMed ID: 32972438
[TBL] [Abstract][Full Text] [Related]
46. CCMCL1: a new model of aggressive mantle cell lymphoma.
Zhao X; Chen-Kiang S; Shetty S; Di Liberto M; Bodo J; Durkin L; Eng K; Elemento O; Smith MR; Hsi ED
Blood; 2015 Apr; 125(17):2730-2. PubMed ID: 25907904
[No Abstract] [Full Text] [Related]
47. What lies beneath: Cutaneous involvement of mantle cell lymphoma underlying an insect-bite-like reaction.
Shah RA; Powell PR; Parekh PK
J Cutan Pathol; 2021 Apr; 48(4):563-566. PubMed ID: 32776338
[TBL] [Abstract][Full Text] [Related]
48. Bilateral Infiltrative Optic Neuropathy of Systemic Mantle Cell Lymphoma.
Aldrees S; Jeeva-Patel T; Margolin E
Can J Neurol Sci; 2020 May; 47(3):428-430. PubMed ID: 32046809
[No Abstract] [Full Text] [Related]
49. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
50. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
[No Abstract] [Full Text] [Related]
51. Mantle cell lymphoma mainly involving thoracic lesions: two case reports.
Kosaka M; Koizumi T; Fukushima T; Wada Y; Agatsuma T; Yokoyama T; Kanda S; Kubo K; Shimojo H; Horie S; Asano N
Intern Med; 2011; 50(14):1477-81. PubMed ID: 21757833
[TBL] [Abstract][Full Text] [Related]
52. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
[TBL] [Abstract][Full Text] [Related]
53. An Uncommon Case of Double-Hit Mantle Cell Lymphoma That Demonstrates a Transformation Process.
Zhou J; Hu L; Zuo M; Zhou Y; Li G; Zhang X
Am J Clin Pathol; 2020 Jan; 153(1):49-57. PubMed ID: 31433838
[TBL] [Abstract][Full Text] [Related]
54. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
[No Abstract] [Full Text] [Related]
55. SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis.
Meggendorfer M; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2013 Dec; 27(12):2388-91. PubMed ID: 23648671
[No Abstract] [Full Text] [Related]
56. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
57. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.
Mohanty A; Sandoval N; Das M; Pillai R; Chen L; Chen RW; Amin HM; Wang M; Marcucci G; Weisenburger DD; Rosen ST; Pham LV; Ngo VN
Oncotarget; 2016 Nov; 7(45):73558-73572. PubMed ID: 27713153
[TBL] [Abstract][Full Text] [Related]
58. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.
Fu S; Wang M; Zhao H; Li R; Lairson DR; Giordano SH; Zhao B; Du XL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e616-e623. PubMed ID: 31563564
[TBL] [Abstract][Full Text] [Related]
59. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of
Eskelund CW; Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Pedersen LB; Geisler CH; Jerkeman M; Grønbæk K
Haematologica; 2018 Nov; 103(11):e541-e543. PubMed ID: 29794145
[No Abstract] [Full Text] [Related]
60. Mantle cell lymphoma lacking the t(11;14) translocation: a case report and brief review of the literature.
Hunt KE; Reichard KK; Wilson CS
J Clin Pathol; 2008 Jul; 61(7):869-70. PubMed ID: 18587018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
